埃索美拉唑镁(Esomeprazole Magnesium) - 药物靶点：Proton pump_在研适应症：吻合口溃疡，食管炎，幽门螺杆菌感染_专利_临床

概要

基本信息

药物类型

小分子化药

别名

(S)-(−)-omeprazole、(S)-omeprazole、(−)-omeprazole

+ [38]

靶点

Proton pump

作用方式

抑制剂

作用机制

质子泵抑制剂

治疗领域

肿瘤感染消化系统疾病+ [4]

在研适应症

吻合口溃疡食管炎幽门螺杆菌感染+ [10]

非在研适应症

腹痛晚期恶性实体瘤哮喘+ [24]

原研机构

AstraZeneca PLC

在研机构

阿斯利康制药有限公司

Daiichi Sankyo Co., Ltd.AstraZeneca Pharmaceuticals LP

+ [9]

非在研机构

Dexcel Pharma Technologies Ltd.

权益机构-

最高研发阶段批准上市

首次获批日期

奥地利 (2000-12-07),

胃食管反流

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)

登录后查看时间轴

结构/序列

分子式C34H36MgN6O6S2

InChIKeyKWORUUGOSLYAGD-UHFFFAOYSA-N

CAS号95382-33-5

关联

537

项与埃索美拉唑镁相关的临床试验

NCT06953986

/ Not yet recruitingN/AIIT

Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks

Primary Objective
• To compare the healing rates of LA grade B or higher reflux esophagitis at 8 weeks among patients treated with Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg once daily.
Secondary Objectives
* To assess the improvement in reflux symptoms using the GERD-Q score at 8 weeks.
* To evaluate the incidence of adverse events across treatment groups.

开始日期2025-05-10

申办/合作机构

Asian Institute of Gastroenterology Pvt Ltd.

CTR20251335

/ Active, not recruiting临床1期

H2受体拮抗剂（盐酸雷尼替丁片）和质子泵抑制剂（奥美拉唑镁肠溶片）对HS-10365药代动力学影响的研究

评估H2受体拮抗剂（盐酸雷尼替丁片）和质子泵抑制剂（奥美拉唑镁肠溶片）对HS-10365药代动力学影响的研究

开始日期2025-04-24

申办/合作机构

江苏豪森药业集团有限公司

TCTR20250224003

/ Not yet recruiting临床1期IIT

Bioequivalence study of esomeprazole 20 mg tablets in healthy Thai volunteers under fasting and fed conditions

开始日期2025-04-07

申办/合作机构-

100 项与埃索美拉唑镁相关的临床结果

登录后查看更多信息

100 项与埃索美拉唑镁相关的转化医学

登录后查看更多信息

100 项与埃索美拉唑镁相关的专利（医药）

登录后查看更多信息

459

项与埃索美拉唑镁相关的文献（医药）

2025-04-20·Journal of Audiology and Otology

Preliminary Analysis of Drug-Induced Ototoxicity in South Korea: Trends From a National Sample Dataset

Article

作者: Seo, Young Joon ; Yoon, Chul Young ; Aldahan, Zahra ; Kim, Jiwon ; Park, Kyoung Ho

Background and Objectives: Certain medications are associated with ototoxicity. This study assesses drug-induced ototoxicity in South Korea by analyzing the Korean national health data. Subjects and Methods: Hospital records of National Health Insurance members from 2009 to 2016 were reviewed. Data were compared between patients with and without hearing loss (HL). Individuals with HL were identified as having a primary diagnosis code for sensorineural HL or another type of HL in at least one outpatient or inpatient record according to the International Classification of Diseases-10. Results: The members in the HL group increased slightly from 0.8% to 1.0% relative to the total sample, compared with 99.2% to 99.0% among the controls. The proportion of males in the HL group ranged from 45.6% to 47.6%, compared with 48.4% to 48.8% among the controls. The proportion of those aged ≥65 years in the HL group increased from 34.1% to 41.4%, compared with 10.6% to 13.3% among the controls. Hypertension prevalence (24.7%-25.7%) in the HL group was higher than that in the control group (12%-12.6%). Diabetes prevalence in the HL group was 10.6%-12.3%, compared with 4.4%-5.9% among the controls. The use of proton pump inhibitor components increased, particularly esomeprazole magnesium trihydrate and rabeprazole sodium, whereas the usage of pantoprazole sodium sesquihydrate and revaprazan was high initially but declined subsequently. The usage of painkillers such as acetaminophen, loxoprofen sodium, and ibuprofen remained high, and antibiotics such as cephalosporins indicated the highest usage. However, the use of penicillin antibiotics such as amoxicillin decreased significantly. Anticancer agents showed relatively low usage compared with other drug categories, whereas antihistamines showed extremely high usage across all years, with a continual increase. Conclusions: These correlations and the underlying mechanisms necessitate further investigation, as several medicines have been linked to an increased risk of HL.

2025-02-01·JOURNAL OF CHROMATOGRAPHY A

Automatic monitoring and on-line chiral separation of chiral drug synthesis

Article

作者: Chi, Zhongmei ; Liu, Guocheng ; Chu, Shiqi ; Gu, Jiali

Chiral synthesis of single chiral drugs offers high efficiency, controllable costs, and excellent enantioselectivity, making it crucial in the pharmaceutical industry. A significant number of studies on chiral drug synthesis primarily focuses on the design and synthesis of innovative chiral catalysts and ligands with extremely high selectivity, as well as the development of new methods and strategies. Nonetheless, the on-line monitoring of chiral drug synthesis and its underlying mechanisms remain obscure. The principal challenge lies in the diverse synthesis pathways and intricate mechanisms of chiral drugs, with numerous intermediates and by-products. To tackle this issue, employing the chiral drug omeprazole as a breakthrough, we design and establish a reliable and stable analytical method to monitor the synthesis process. By integrating electrokinetic chromatography technology with automatic sequence injection, the chiral synthesis of omeprazole can be comprehensively tracked and monitored throughout its entire process. During the chiral drug synthesis process, all compounds, containing all reagents and products (omeprazole sulfide, R-omeprazole, S-omeprazole, iodobenzene and iodobenzene diacetate) are efficiently separated and simultaneously detected through a single run. The method shows a high resolution greater than 1.2, a wide linear range with a detection limit as low as 0.008 μM, as well as exceptional repeatability in sequence analysis. Therefore, the proposed method has demonstrated significant value in the analysis of chiral drug synthesis and holds potential for extensive application in the industrial production of chiral compound synthesis.

2025-01-25·The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi

Efficacy and Safety of Dual Delayed-Release Formulation of Esomeprazole in Patients with Gastroesophageal Reflux Disease: A Multicenter, Prospective, Observational Study

Article

作者: Park, Moon-hwa ; Lim, Hyun

Background/Aims:

Gastroesophageal reflux disease (GERD) is a chronic and recurrent condition requiring constant dietary management and medication. This study evaluated the efficacy and safety of HIP1601, a dual delayed-release formulation of esomeprazole, in patients with GERD in a clinical setting.

Methods:

This prospective, multicenter, observational study was conducted at 309 medical institutions in Korea between June 2021 and March 2023. HIP1601 was administered at daily doses of 40 mg or 20 mg to 5,407 patients requiring treatment or prevention of erosive esophagitis. The primary outcome was the improvement rate of GERD symptoms at four weeks. GERD-related symptoms and treatment-emergent adverse events were also analyzed.

Results:

This study included 5,282 patients in the safety analysis set and 5,232 in the full analysis set. At four weeks, the improvement rate of GERD symptoms was 92.1% (95% confidence interval [CI]: 91.3-92.8%). By eight weeks, the improvement rate increased to 94.6% (95% CI: 94.0-95.3%). After HIP1601 administration, the severity scores for all four GERD symptoms decreased to less than 1, with statistically significant changes in the scores (p<0.001). HIP1601 was well-tolerated, with minimal adverse events reported (0.17%), and the treatment-emergent adverse events were mild to moderate in severity.

Conclusions:

HIP1601 showed strong efficacy and safety in managing GERD symptoms, with high rates of symptom relief at four and eight weeks. Its extended action and improved symptom control make it a promising therapeutic option for GERD patients.

336

项与埃索美拉唑镁相关的新闻（医药）

2025-06-02

·PRNewswire

Grünenthal announces acquisition of the rights to Cialis® from Lilly in Mexico, Brazil & Colombia

Grünenthal announces that it agreed to acquire the commercial rights to Cialis® from Eli Lilly and Company in Mexico, Brazil and Colombia, further strengthening Grünenthal's footprint in Latin America. As part of the acquisition, Grünenthal will transfer the manufacturing of Cialis® to its production site in Chile. Since 2017, Grünenthal has invested more than €2 billion in successful M&A transactions, significantly strengthening its profitability. AACHEN, Germany, June 2, 2025 /PRNewswire/ -- Grünenthal today announced the acquisition of the commercial rights to Cialis® (tadalafil) in Mexico, Brazil and Colombia from Eli Lilly and Company. Over the next few years, Grünenthal and Lilly will work together to transfer the manufacturing to Grünenthal's production site in Santiago, Chile, that will supply Cialis® for Mexico, Brazil and Colombia moving forward. The transaction is expected to close in the third quarter of 2025, subject to the satisfaction of customary closing conditions. Grünenthal will finance the transaction using available liquidity. The financial terms of the transaction are not disclosed. Cialis® is indicated for the oral treatment of erectile dysfunction and signs and symptoms of benign prostatic hyperplasia in adult men[1]. The acquisition will expand Grünenthal's Latin American Men's Health product portfolio. "Executing on our strategy of targeted acquisitions, Cialis® will expand our existing portfolio in the region and strengthen Grünenthal's Latin American business", says Gabriel Baertschi, CEO, Grünenthal. "In 2022, we acquired Nebido®, a long-acting treatment for testosterone deficiency, and with Cialis® we can continue to serve our existing customer base and foster our growth in key Latin American markets." Through the acquisition of Cialis®, Grünenthal continues executing its strategy of acquiring established medicines to expand its portfolio and increase its profitability. Since 2017, Grünenthal has invested over €2 billion in the acquisition of established medicines, including Nebido®, the European rights to Crestor® and Nexium®, as well as the global rights to Vimovo® (excluding the U.S. and Japan), Qutenza® and Zomig® (excluding Japan). In 2023, Grünenthal established Grünenthal Meds, a joint venture with Kyowa Kirin International, which manages a portfolio of 13 brands primarily focused on pain management and, in 2024, acquired the US company Valinor Pharma and the product Movantik®. About Grünenthal Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We focus all our activities and efforts on working towards our vision of a World Free of Pain. Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America, and the U.S. Our products are available in approx. 100 countries. In 2024, Grünenthal employed around 4,300 people and achieved revenues of €1.8 billion. More information: Follow us on: LinkedIn: Grunenthal Group Instagram: grunenthal For further information, please contact: Maren Thurow Head Global Communication Grünenthal GmbH 52099 Aachen E-Mail: [email protected] Phone: +44 7917 196855 [1] In Mexico Cialis® is indicated for the oral treatment of erectile dysfunction and symptoms of benign prostatic hyperplasia in adult men. SOURCE Grünenthal Group WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

并购上市批准

2025-05-19

·药筛

药交会前瞻：最卷的100个药品

参加广州药交会，提前做好产品攻略！纯干货，无废话。这是系列四：2024年1月1日-2025年4月30日获批企业数量排名前100药品。排名药品名称持有人数量1地夸磷索钠滴眼液362间苯三酚注射液343乳果糖口服溶液304米诺地尔搽剂295二羟丙茶碱注射液276玻璃酸钠滴眼液267法莫替丁注射液268他达拉非片269硫酸氨基葡萄糖胶囊2510帕拉米韦注射液2311磷酸奥司他韦干混悬剂2212磷酸奥司他韦胶囊2213己酮可可碱注射液2114氨溴特罗口服溶液2015复方聚乙二醇电解质散(III)1916注射用尼可地尔1917达格列净片1718利丙双卡因乳膏1719罗沙司他胶囊1720吸入用乙酰半胱氨酸溶液1721恩格列净片1622盐酸乌拉地尔注射液1623阿戈美拉汀片1524富马酸福莫特罗吸入溶液1525硫酸镁钠钾口服用浓溶液1526注射用盐酸罗沙替丁醋酸酯1527磷酸西格列汀片1428马来酸阿伐曲泊帕片1429美索巴莫注射液1430盐酸多巴酚丁胺注射液1431吲哚布芬片1432注射用氯诺昔康1433甲钴胺片1334氯化钾颗粒1335氯化钾注射液1336马来酸氟伏沙明片1337普拉洛芬滴眼液1338沙库巴曲缬沙坦钠片1339腺苷钴胺胶囊1340盐酸奥洛他定滴眼液1341盐酸达泊西汀片1342注射用头孢唑肟钠1343二甲双胍恩格列净片(Ⅰ)1244富马酸伏诺拉生片1245盐酸艾司洛尔注射液1246盐酸多巴胺注射液1247盐酸莫西沙星滴眼液1248盐酸莫西沙星氯化钠注射液1249艾曲泊帕乙醇胺片1150普瑞巴林胶囊1151瑞巴派特片1152西格列汀二甲双胍片(Ⅱ)1153盐酸氨溴索口服溶液1154盐酸丙卡特罗口服溶液1155地氯雷他定口服溶液1056非布司他片1057硫酸镁注射液1058麦考酚钠肠溶片1059盐酸去氧肾上腺素注射液1060盐酸左沙丁胺醇雾化吸入溶液1061左氧氟沙星滴眼液1062阿加曲班注射液963枸橼酸西地那非口崩片964拉考沙胺注射液965莫匹罗星软膏966普瑞巴林口服溶液967氢溴酸伏硫西汀片968瑞戈非尼片969重酒石酸间羟胺注射液970重酒石酸去甲肾上腺素注射液971注射用头孢他啶阿维巴坦钠972左乙拉西坦口服溶液973阿司匹林肠溶片874布洛芬混悬液875地诺孕素片876多巴丝肼片877多索茶碱注射液878二甲双胍恩格列净片(Ⅵ)879甲硫酸新斯的明注射液880聚乙烯醇滴眼液881硫酸羟氯喹片882铝碳酸镁咀嚼片883米拉贝隆缓释片884舒更葡糖钠注射液885碳酸氢钠林格注射液886头孢地尼颗粒887吸入用硫酸沙丁胺醇溶液888硝酸异山梨酯注射液889熊去氧胆酸胶囊890溴芬酸钠滴眼液891依折麦布片892左卡尼汀口服溶液893艾司奥美拉唑镁肠溶胶囊794奥拉帕利片795奥美沙坦酯氨氯地平片796奥硝唑注射液797倍他米松磷酸钠注射液798吡拉西坦注射液799富马酸丙酚替诺福韦片7100钆特酸葡胺注射液7101枸橼酸托法替布片7102骨化三醇软胶囊7103甲磺酸雷沙吉兰片7104酒石酸溴莫尼定滴眼液7105聚乙二醇4000散7106利奈唑胺葡萄糖注射液7107硫酸沙丁胺醇注射液7108硫酸特布他林雾化吸入用溶液7109罗库溴铵注射液7110洛索洛芬钠凝胶贴膏7111氯化钾口服溶液7112他氟前列素滴眼液7113碳酸镧咀嚼片7114维格列汀片7115西甲硅油乳剂7116吸入用复方异丙托溴铵溶液7117吸入用盐酸丙卡特罗溶液7118缬沙坦氨氯地平片(Ⅰ)7119盐酸胺碘酮注射液7120盐酸氮卓斯汀滴眼液7121依帕司他片7122注射用厄他培南钠7123左卡尼汀注射液7124左西孟旦注射液7125左氧氟沙星氯化钠注射液7126左氧氟沙星片7（手工整理，如有错误或遗漏，欢迎补充）用摩熵药筛小程序，快速查询产品信息。

申请上市

2025-05-13

·PRNewswire

RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win

Korea's Incheon District Court attachment grant prevents asset disposal by Kukbo prior to enforcement, following the New York Supreme Court's approximately $8.25 million plus legal fees and costs summary judgment in favor of RedHill -- The New York Supreme Court dismissed all Kukbo's counterclaims -- Latest Court victory demonstrates RedHill's commitment to collection of the court-mandated award, upon which 9% interest continues to be accruable RALEIGH, N.C. and TEL-AVIV, Israel, May 13, 2025 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it had won its attachment petition to the Court in South Korea on Kukbo Co. Ltd's ("Kukbo") assets, following the approximately $8.25 million plus legal fees and costs summary judgment ruling in RedHill's favor by the New York Supreme Court. An attachment petition in South Korea refers to a court-ordered seizure (attachment) of a debtor's assets to secure a claim before or during a lawsuit, designed to prevent the debtor from disposing of assets before the creditor can enforce a judgment. RedHill's approximately $8.25 million summary judgment win includes approximately $1.75 million in accrued interest at 9%, emanating from Kukbo's failure to pay RedHill according to the terms of subscription and licensing agreements signed by the two companies in October 2021 and March 2022, respectively. Additionally, and in accordance with the court's ruling, a motion has been filed to recover legal fees and costs. Kukbo has a right to seek an appeal of the judgment, and on December 4, 2024, filed a notice of appeal, upon which they may or may not choose to act. Kukbo has six months from filing of the notice, until June 4, 2025, to perfect its appeal, subject to potential extension. About RedHill Biopharma RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on U.S. development and commercialization of drugs for gastrointestinal diseases, infectious diseases and oncology. RedHill promotes the FDA approved gastrointestinal drug Talicia®, for the treatment of Helicobacter pylori (H. pylori) infection in adults[1], with submission planned for marketing authorization in other territories. RedHill's key clinical late-stage development programs include: (i) opaganib (ABC294640), a first-in-class, orally administered sphingosine kinase-2 (SPHK2) selective inhibitor with anticancer, anti-inflammatory and antiviral activity, targeting multiple indications with U.S. government and academic collaborations for development for radiation and chemical exposure indications such as Gastrointestinal-Acute Radiation Syndrome (GI-ARS), a Phase 2 study in prostate cancer in combination with Bayer's darolutamide and a Phase 2/3 program for hospitalized COVID-19 patients; (ii) RHB-204 with a planned Phase 2 study for Crohn's disease and Phase 3-stage for pulmonary nontuberculous mycobacterial (NTM) disease; (iii) RHB-104, with positive results from a first Phase 3 study for Crohn's disease; (iv) RHB-107 ( upamostat), an oral broad-acting, host-directed, serine protease inhibitor with potential for pandemic preparedness, is in late-stage development as a treatment for non-hospitalized symptomatic COVID-19 and is also targeting multiple other cancer and inflammatory gastrointestinal diseases; and (v) RHB-102, with potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting, positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D. RHB-102 is partnered with Hyloris Pharma (EBR: HYL) for worldwide development and commercialization outside North America. More information about the Company is available at / X.com/RedHillBio. Forward Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and may discuss investment opportunities, stock analysis, financial performance, investor relations, and market trends. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words and include, among others, statements regarding the potential outcome of litigation against Kukbo Co. Ltd. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: the risk that the Company's attempts to receive the judgment awarded against Kukbo by the New York Supreme Court may not be successful; the risk that the Company may not submit a UK MAA for Talicia and if it does that submission may not be successful; the risk that the development of RHB-204 for Crohn's disease may not be completed and if completed may not be successful; the risk that the Company will not benefit from its agreement with Hyloris as currently anticipated; the Company's ability to maintain compliance with the Nasdaq Capital Market's listing requirements; the risk that the addition of new revenue generating products or out-licensing transactions will not occur; the risk of current uncertainty regarding U.S. government research and development funding and that the U.S. government is under no obligation to continue to support development of our products and can cease such support at any time; the risk that acceptance onto the RNCP Product Development Pipeline or other governmental and non-governmental development programs will not guarantee ongoing development or that any such development will not be completed or successful; the risk that the FDA does not agree with the Company's proposed development plans for its programs; the risk that observations from preclinical studies are not indicative or predictive of results in clinical trials; the risk that the Company's development programs and studies may not be successful and, even if successful, such studies and results may not be sufficient for regulatory applications, including emergency use or marketing applications, and that additional studies may be required; the risk of market and other conditions and that the Company will not successfully commercialize its products; as well as risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company's research, manufacturing, pre-clinical studies, clinical trials, and other therapeutic candidate development efforts, and the timing of the commercial launch of its commercial products and ones it may acquire or develop in the future; (ii) the Company's ability to advance its therapeutic candidates into clinical trials or to successfully complete its pre-clinical studies or clinical trials or the development of any necessary commercial companion diagnostics; (iii) the extent and number and type of additional studies that the Company may be required to conduct and the Company's receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company's therapeutic candidates and Talicia; (v) the Company's ability to successfully commercialize and promote Talicia; (vi) the Company's ability to establish and maintain corporate collaborations; (vii) the Company's ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company's therapeutic candidates and the results obtained with its therapeutic candidates in research, pre-clinical studies or clinical trials; (ix) the implementation of the Company's business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xii) estimates of the Company's expenses, future revenues, capital requirements and needs for additional financing; (xiii) the effect of patients suffering adverse experiences using investigative drugs under the Company's Expanded Access Program; (xiv) competition from other companies and technologies within the Company's industry; and (xv) the hiring and employment commencement date of executive managers. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 20-F filed with the SEC on April 8, 2024. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise unless required by law. Company contact: Adi Frish Chief Corporate & Business Development Officer RedHill Biopharma +972-54-6543-112 [email protected] Category: Corporate [1] Talicia® (omeprazole magnesium, amoxicillin and rifabutin) is indicated for the treatment of H. pylori infection in adults. For full prescribing information see: . Logo: SOURCE RedHill Biopharma Ltd. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床2期临床结果临床3期上市批准

100 项与埃索美拉唑镁相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01984	埃索美拉唑镁	A02BC05	DB00736

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
吻合口溃疡	日本	Sawai Pharmaceutical Co., Ltd.	2022-08-15
食管炎	美国	Covis Pharma Holdings BV	2016-02-03
幽门螺杆菌感染	日本	AstraZeneca KK	2013-02-21
抗血小板药物引起的十二指肠溃疡	日本	阿斯利康制药有限公司	2012-06-22
反流性食管炎	澳大利亚	AstraZeneca Pty Ltd.	2010-12-22
胃十二指肠疾病	澳大利亚	AstraZeneca Pty Ltd.	2010-12-22
糜烂性食管炎	美国	Covis Pharma Holdings BV	2008-03-20
Zollinger-Ellison综合征	美国	AstraZeneca Pharmaceuticals LP	2006-10-11
胃灼热	美国	AstraZeneca Pharmaceuticals LP	2003-06-20
胃溃疡	中国	AstraZeneca PLC	2002-10-16
十二指肠溃疡	美国	AstraZeneca Pharmaceuticals LP	2001-02-20
胃食管反流	奥地利	Grünenthal GmbH	2000-12-07
胃食管反流	比利时	Grünenthal GmbH	2000-12-07
胃食管反流	丹麦	Grünenthal GmbH	2000-12-07
胃食管反流	芬兰	Grünenthal GmbH	2000-12-07
胃食管反流	法国	Grünenthal GmbH	2000-12-07
胃食管反流	德国	Grünenthal GmbH	2000-12-07
胃食管反流	希腊	Grünenthal GmbH	2000-12-07
胃食管反流	冰岛	Grünenthal GmbH	2000-12-07
胃食管反流	爱尔兰	Grünenthal GmbH	2000-12-07

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
应激性溃疡	临床3期	中国	AstraZeneca PLC	2014-07-01
非糜烂性反流病	临床3期	日本	AstraZeneca PLC	2014-06-01
出血	临床3期	中国	阿斯利康制药有限公司	2013-02-26
腰痛	临床3期	日本	AstraZeneca PLC	2007-08-01
骨关节炎	临床3期	日本	AstraZeneca PLC	2007-08-01
类风湿关节炎	临床3期	日本	AstraZeneca PLC	2007-08-01
十二指肠糜烂	临床3期	美国	AstraZeneca PLC	2007-02-01
十二指肠糜烂	临床3期	阿根廷	AstraZeneca PLC	2007-02-01
十二指肠糜烂	临床3期	澳大利亚	AstraZeneca PLC	2007-02-01
十二指肠糜烂	临床3期	保加利亚	AstraZeneca PLC	2007-02-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


UEGW2024	N/A	感染一线	439	EA (esomeprazole-amoxicillin)	廠遞築餘繭繭範蓋鏇願(膚醖觸獵廠膚鑰簾鑰夢) = 簾鬱壓範衊顧構構網壓衊餘築餘鹹願網淵鏇艱 (衊壓鹽廠願鹽鹹蓋網鑰 )	积极	2024-10-13
				B-quadruple (esomeprazole-amoxicillin-clarithromycin-bismuth)	廠遞築餘繭繭範蓋鏇願(膚醖觸獵廠膚鑰簾鑰夢) = 糧餘網廠願壓廠壓顧範衊餘築餘鹹願網淵鏇艱 (衊壓鹽廠願鹽鹹蓋網鑰 )
NCT06382493 (Pubmed \| Helicobacter)	N/A	幽门螺杆菌感染	406	Esomeprazole-containing sequential therapy	廠餘憲蓋窪衊選淵襯鑰(夢願糧壓簾淵糧築鬱糧) = Nausea was more prevalent (23.3%, 27/202) with sequential tegoprazans than with esomeprazole-containing sequential therapy (14.2%, 29/204; p = 0.022) 齋構築積淵醖蓋醖廠膚 (鹽願選遞網鑰淵齋膚糧 )	积极	2024-09-01
				Tegoprazan-containing sequential therapy
NCT05265247 (CTgov)	临床1期	胃肠道疾病	61	Esomeprazole (Esomeprazole CG (Test))	窪鹽遞觸構廠鏇鏇積糧(網鑰膚願壓蓋鑰鏇觸繭) = 糧鹽鏇鏇廠網繭網鬱壓窪憲淵淵夢醖窪憲壓鹹 (窪鏇構鏇廠憲夢齋廠壓, 51.1) 更多	-	2024-02-05
				Esomeprazole AZ (Esomeprazole AZ (Reference))	窪鹽遞觸構廠鏇鏇積糧(網鑰膚願壓蓋鑰鏇觸繭) = 糧製鏇選膚壓醖膚鹹遞窪憲淵淵夢醖窪憲壓鹹 (窪鏇構鏇廠憲夢齋廠壓, 46.2) 更多
NCT04080726 (HIP1601, Pubmed \| BMC Gastroenterol)	临床3期	糜烂性食管炎	213	HIP1601 40 mg	壓積齋鬱築鬱網築醖鑰(鹹艱鑰鹽獵憲廠襯齋築) = 鏇窪憲衊築膚鏇簾鏇繭淵夢壓廠衊膚窪鹹窪積 (範淵膚築選廠觸繭餘廠, -4.7 ~ 7.2)	积极	2023-12-18
				HGP1705 40 mg	壓積齋鬱築鬱網築醖鑰(鹹艱鑰鹽獵憲廠襯齋築) = 積觸糧顧網範膚餘選繭淵夢壓廠衊膚窪鹹窪積 (範淵膚築選廠觸繭餘廠, -4.7 ~ 7.2)
UEGW2022	N/A	糜烂性食管炎	-	HIP1601 40mg	蓋襯蓋憲鑰鑰構鏇鬱憲(窪積壓鬱觸網觸鹹衊壓) = 膚積簾膚繭憲艱齋艱衊觸蓋構顧繭網獵獵憲構 (鹹觸衊鹽顧築觸餘鬱襯, -4.7 ~ 7.2)	积极	2022-10-09
				HGP1705 40mg	蓋襯蓋憲鑰鑰構鏇鬱憲(窪積壓鬱觸網觸鹹衊壓) = 膚糧淵願鬱衊壓範餘襯觸蓋構顧繭網獵獵憲構 (鹹觸衊鹽顧築觸餘鬱襯 )
UEGW2022	N/A	幽门螺杆菌感染	-	Vonoprazan-based quadruple therapy	積鹽蓋築淵憲餘鏇願繭(鏇鬱獵憲憲淵衊製餘夢) = Dysgeusia was most frequently reported in 68.2% and 81.8% of subjects receiving vonoprazan and esomeprazole, respectively. 艱網衊範繭鹹艱鏇願遞 (齋選製憲願齋獵淵網衊 )	-	2022-10-09
				Esomeprazole-based quadruple therapy
NCT04678492 (Pubmed \| Chin Med J (Engl)) 人工标引	临床4期	幽门螺杆菌感染	658	Esomeprazole+Amoxicillin Trihydrate (High-dose dual therapy)	夢衊獵顧遞襯鬱獵襯壓(簾願積廠選衊構齋繭簾) = 顧窪餘餘積範獵餘鹹觸鏇獵衊鬱積願淵餘網膚 (糧願襯遞鏇醖範窪鹹蓋 ) 更多	不佳	2022-07-20
				Esomeprazole+Bismuth Potassium Citrate+Furazolidone+tetracycline (bismuth-containing quadruple therapy)	夢衊獵顧遞襯鬱獵襯壓(簾願積廠選衊構齋繭簾) = 繭鏇齋夢簾鹽廠憲製憲鏇獵衊鬱積願淵餘網膚 (糧願襯遞鏇醖範窪鹹蓋 ) 更多
DDW2022	N/A	-	-	Proton pump inhibitor (PPI) + amoxicillin + clarithromycin (PPI-based triple)	齋繭獵廠廠餘積鹽糧築(醖憲簾鑰繭積獵衊顧襯): OR = 2.17 (95% CI, 1.08 ~ 4.35)	-	2022-05-24
				Omeprazole magnesium + amoxicillin + rifabutin delayed-release (rifabutin triple therapy; RT-DR)
NCT03849690 (Pubmed \| Clin Transl Sci)	临床1期	-	12	Trazpiroben 25 mg alone	廠繭憲築鬱鏇襯艱壓襯(淵構範鬱願襯衊選範獵) = 鬱願願繭遞鏇鹹鬱鬱艱夢鑰選齋鬱壓範窪選壓 (製積構鬱齋製顧廠選簾 ) 更多	积极	2022-02-26
				Trazpiroben 25 mg + Esomeprazole 40 mg	廠繭憲築鬱鏇襯艱壓襯(淵構範鬱願襯衊選範獵) = 顧襯糧膚齋鏇觸鑰簾夢夢鑰選齋鬱壓範窪選壓 (製積構鬱齋製顧廠選簾 ) 更多
NCT01983774 (CTgov)	临床2期	囊性纤维化	21	Esomeprazole (Esomeprazole)	選窪壓鑰淵餘構鹹鏇蓋(獵製襯憲繭齋獵鹽淵鏇) = 鑰鑰遞願鬱襯醖窪廠鹽壓鹽夢蓋淵餘窪壓構繭 (網遞鬱壓製蓋選製鏇積, NA) 更多	-	2022-02-17
				Placebo (Placebo)	選窪壓鑰淵餘構鹹鏇蓋(獵製襯憲繭齋獵鹽淵鏇) = 糧鹹製構願醖壓糧膚衊壓鹽夢蓋淵餘窪壓構繭 (網遞鬱壓製蓋選製鏇積, NA) 更多